DE69828330T2 - Aktiviertes Protein C Formulierungen - Google Patents

Aktiviertes Protein C Formulierungen Download PDF

Info

Publication number
DE69828330T2
DE69828330T2 DE69828330T DE69828330T DE69828330T2 DE 69828330 T2 DE69828330 T2 DE 69828330T2 DE 69828330 T DE69828330 T DE 69828330T DE 69828330 T DE69828330 T DE 69828330T DE 69828330 T2 DE69828330 T2 DE 69828330T2
Authority
DE
Germany
Prior art keywords
formulation according
formulation
activated protein
apc
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828330T
Other languages
German (de)
English (en)
Other versions
DE69828330D1 (de
Inventor
Andrew David Indianapolis Carlson
Theodore Arsay Indianapolis Sheliga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69828330D1 publication Critical patent/DE69828330D1/de
Publication of DE69828330T2 publication Critical patent/DE69828330T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69828330T 1997-04-28 1998-04-28 Aktiviertes Protein C Formulierungen Expired - Lifetime DE69828330T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
US45255P 1997-04-28

Publications (2)

Publication Number Publication Date
DE69828330D1 DE69828330D1 (de) 2005-02-03
DE69828330T2 true DE69828330T2 (de) 2005-10-13

Family

ID=21936854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828330T Expired - Lifetime DE69828330T2 (de) 1997-04-28 1998-04-28 Aktiviertes Protein C Formulierungen

Country Status (35)

Country Link
US (4) US6162629A (fr)
EP (2) EP0875563A3 (fr)
JP (2) JP4383546B2 (fr)
KR (2) KR100564189B1 (fr)
CN (2) CN1235638C (fr)
AR (2) AR012010A1 (fr)
AT (1) ATE285788T1 (fr)
AU (2) AU740753C (fr)
BR (2) BR9809292A (fr)
CA (2) CA2288143C (fr)
CO (2) CO4940438A1 (fr)
CZ (1) CZ298429B6 (fr)
DE (1) DE69828330T2 (fr)
DK (1) DK0875252T3 (fr)
EA (2) EA004881B1 (fr)
EG (1) EG23685A (fr)
ES (1) ES2234072T3 (fr)
HK (1) HK1016472A1 (fr)
HU (2) HUP0003401A3 (fr)
ID (2) ID22933A (fr)
IL (2) IL132502A0 (fr)
IN (2) IN187157B (fr)
MY (2) MY120984A (fr)
NO (2) NO995134L (fr)
NZ (2) NZ500346A (fr)
PE (2) PE84799A1 (fr)
PL (2) PL195090B1 (fr)
PT (1) PT875252E (fr)
SI (1) SI0875252T1 (fr)
SV (2) SV1998000050A (fr)
TR (2) TR199902529T2 (fr)
TW (2) TWI242443B (fr)
UA (2) UA73071C2 (fr)
WO (2) WO1998048818A1 (fr)
ZA (2) ZA983497B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22933A (id) 1997-04-28 1999-12-16 Lilly Co Eli Fomulasi protien c terakivasi
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CA2351067A1 (fr) * 1998-11-13 2000-05-25 Eli Lilly And Company Traitement de la thrombopenie immunitaire de l'heparine
EP1131091B1 (fr) * 1998-11-20 2003-04-02 Eli Lilly And Company Traitement des fievres virales hemorragiques avec de la proteine c
CN1326357A (zh) * 1998-11-23 2001-12-12 伊莱利利公司 治疗镰刀形红细胞贫血病及地中海贫血病的方法
EP1137432B1 (fr) * 1998-12-10 2004-04-14 Eli Lilly And Company Utilisation de la protein c pour le traitement du purpura thrombopenique et du syndrome hemolytique et uremique
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) * 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
HUP0303199A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
WO2003024398A2 (fr) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Traitement de la sepsie avec tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
WO2003055442A2 (fr) 2001-10-15 2003-07-10 Chiron Corporation Traitement d'une maladie infectieuse par l'administration d'une faible dose d'un inhibiteur de voie d'acces de thromboplastine tissulaire (tfpi)
EP1458408B1 (fr) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Composition liquide de polypeptides de facteur vii
WO2003075834A2 (fr) * 2002-03-08 2003-09-18 Eli Lilly And Company Formulations de proteines c activees
EP1517698B2 (fr) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG COMPOSITIONS SOLIDES STABILISEES DE POLYPEPTIDES DE FACTEUR VIIa
RU2329823C2 (ru) * 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
EP1729791A2 (fr) * 2004-03-17 2006-12-13 Chiron Corporation Traitement de la pneumonie extra-hospitalière grave par administration de l'inhibiteur de parcours de facteur tissu (tfpi)
WO2006014839A2 (fr) * 2004-07-23 2006-02-09 The University Of Rochester La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau
EP1913155A4 (fr) * 2005-06-23 2009-08-12 Univ British Columbia Polymorphismes de facteur de coagulation iii associes a une prediction relative aux resultats et a la reponse d'un sujet a une therapie
ES2386972T3 (es) * 2006-05-31 2012-09-10 Genzyme Corporation Uso de polisacáridos para la estimulación de la actividad enzimática
CA2654761A1 (fr) * 2006-06-09 2007-12-13 The University Of British Columbia Polymorphismes de l'interferon gamma utilises comme indicateurs de resultat chez des sujets gravement malades
WO2008107908A1 (fr) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprenant des conjugués de peg-interféron alpha et de la raffinose en tant que cryoprotecteur
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (fr) 2010-11-19 2012-05-24 Sirius Genomics Inc. Marqueurs associés à la réponse à une administration de la protéine c activée, et leurs utilisations
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
EP2834635A4 (fr) 2012-04-03 2015-09-02 Smiths Medical Asd Inc Compositions d'agents de charge d'héparine et procédés associés
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
EP2869833B1 (fr) 2012-07-04 2018-04-04 ZZ Biotech LLC. Protéine c activée pour traitement de troubles cutanés inflammatoires
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
WO2015157791A1 (fr) 2014-04-16 2015-10-22 The University Of Sydney Traitement de cicatrices cutanées anormales
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
EP3463308B1 (fr) * 2016-06-01 2021-12-01 Servier IP UK Limited Formulations d'oxyde de polyalkylène-asparaginase et leurs procédés de fabrication et d'utilisation
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (fr) * 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (fr) 1995-11-30 1997-06-05 Zymogenetics, Inc. Production de proteine c chez des animaux transgeniques
ID22933A (id) 1997-04-28 1999-12-16 Lilly Co Eli Fomulasi protien c terakivasi
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP0875252B1 (fr) 2004-12-29
ZA983496B (en) 1999-10-25
BR9809292A (pt) 2000-07-04
ID22933A (id) 1999-12-16
TW585871B (en) 2004-05-01
US6436397B1 (en) 2002-08-20
KR100564189B1 (ko) 2006-03-27
US6159468A (en) 2000-12-12
NO995134D0 (no) 1999-10-21
US6162629A (en) 2000-12-19
HK1016472A1 (en) 1999-11-05
TR199902529T2 (xx) 2000-02-21
IL132325A (en) 2005-07-25
CN1254284A (zh) 2000-05-24
KR100450856B1 (ko) 2004-10-02
JP2001524111A (ja) 2001-11-27
HUP0003401A2 (hu) 2001-02-28
WO1998048818A1 (fr) 1998-11-05
CA2287267C (fr) 2006-08-15
EA004881B1 (ru) 2004-08-26
IN187157B (fr) 2002-02-16
AU740753B2 (en) 2001-11-15
IN183798B (fr) 2000-04-15
US6395270B1 (en) 2002-05-28
HUP0100284A2 (hu) 2001-06-28
CO4940438A1 (es) 2000-07-24
NO995198L (no) 1999-10-25
EP0875563A2 (fr) 1998-11-04
NO995134L (no) 1999-12-21
AU743531B2 (en) 2002-01-31
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
PL195090B1 (pl) 2007-08-31
DK0875252T3 (da) 2005-04-25
JP4383546B2 (ja) 2009-12-16
ATE285788T1 (de) 2005-01-15
CZ381099A3 (cs) 2000-03-15
TR199902631T2 (xx) 2000-01-21
NZ500346A (en) 2001-08-31
PL336889A1 (en) 2000-07-17
ES2234072T3 (es) 2005-06-16
EP0875563A3 (fr) 2000-08-02
EP0875252A3 (fr) 2000-07-26
ZA983497B (en) 1999-10-25
CN1235638C (zh) 2006-01-11
PE84799A1 (es) 1999-09-16
AR012010A1 (es) 2000-09-13
UA73071C2 (en) 2005-06-15
CN1261280A (zh) 2000-07-26
ID23172A (id) 2000-03-23
HUP0003401A3 (en) 2003-01-28
MY118591A (en) 2004-12-31
AU740753C (en) 2002-10-10
AU7258998A (en) 1998-11-24
BR9809304A (pt) 2000-10-17
PT875252E (pt) 2005-03-31
AU7161898A (en) 1998-11-24
EA002149B1 (ru) 2001-12-24
CA2287267A1 (fr) 1998-11-05
CZ298429B6 (cs) 2007-10-03
CN1227025C (zh) 2005-11-16
PE86299A1 (es) 1999-09-17
SV1998000051A (es) 1998-12-11
BR9809304B1 (pt) 2011-02-08
SV1998000050A (es) 1999-01-13
PL336420A1 (en) 2000-06-19
DE69828330D1 (de) 2005-02-03
KR20010020242A (ko) 2001-03-15
PL195642B1 (pl) 2007-10-31
CA2288143A1 (fr) 1998-11-05
AR015598A1 (es) 2001-05-16
IL132325A0 (en) 2001-03-19
IL132502A0 (en) 2001-03-19
KR20010020325A (ko) 2001-03-15
HUP0100284A3 (en) 2003-08-28
EG23685A (en) 2007-05-09
NO995198D0 (no) 1999-10-25
EA199900980A1 (ru) 2000-04-24
CO4950523A1 (es) 2000-09-01
CA2288143C (fr) 2012-08-21
NZ337828A (en) 2001-06-29
EP0875252A2 (fr) 1998-11-04
HU224826B1 (en) 2006-02-28
TWI242443B (en) 2005-11-01
WO1998048822A1 (fr) 1998-11-05
JP2001527543A (ja) 2001-12-25
EA199900979A1 (ru) 2000-06-26
MY120984A (en) 2005-12-30
SI0875252T1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
DE69828330T2 (de) Aktiviertes Protein C Formulierungen
DE69729786T2 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
US6630137B1 (en) Activated protein C formulations
DE69333724T2 (de) Hybrider menschlich-schweinlicher faktor viii
DE3520228C2 (de) Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE60024268T2 (de) Zusammensetzungen mit stabilem faktor viii
DE69828462T2 (de) Verwendung von APC, in Kombination mit Blutplättchenaggregationshemmer, zur Behandlung thrombothischer Störungen
DE3686410T2 (de) Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens.
DE3617752C2 (fr)
EP0796623A2 (fr) Préparation pharmaceutique pour le traitement des maladies de la coagulation sanguine
EP0705846B1 (fr) Les fractions du facteur von Willebrand à haut poids moléculaires et à bas poids moléculaires
DE102006008613A1 (de) Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
EP0382174A1 (fr) Dérivé de l'activateur tissulaire de plasminogène
DE2734427C3 (de) Verfahren zur Gewinnung von thrombinartigen Enzymen aus Schlangengiften
AT409334B (de) Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
EP0833897A2 (fr) Derives de prothrombine
DE69906568T2 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DE69833727T2 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE3586952T2 (de) Fibrinophiler urokinase-komplex und dessen herstellung.
DE69930419T2 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69127757T2 (de) Thrombolytisches peptid, seine produktion und thrombolisches agens
AT405740B (de) Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
US20050143283A1 (en) Activated protein c formulations
DE69916493T2 (de) Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
JP7237085B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN